Get the Stockscreener App
3.88
1.58%
0.08
Bluebird Bio Inc stock is traded at $3.88, with a volume of 93,693.
It is up +1.58% in the last 24 hours and down -50.26% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$3.80
Open:
$3.76
24h Volume:
93,693
Relative Volume:
0.20
Market Cap:
$37.02M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-5.2432
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
-5.39%
1M Performance:
-50.26%
6M Performance:
-69.04%
1Y Performance:
-88.51%
1-Day Range:
$3.72
$4.03
1-Week Range:
$3.56
$4.13
52-Week Range:
$3.56
$34.80
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
3.88 | 37.02M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.99 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.93 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.18 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.99 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.08 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
Turbulence at the FDA & bluebird Bio’s sale - STAT
Drug and Gene Delivery Devices Market Growth in Future Scope - openPR
bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire
BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle
bluebird bio stock slides for second day on buyout news - MSN
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha
JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com
JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq
Troubled gene therapy player bluebird sold for a song - pharmaphorum
Amneal pharma, Aramark, Bluebird Bio - TradingView
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News
bluebird bio announces take-private deal with Carlyle and SK Capital - MSN
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN
Private equity firms rescue bluebird bio out of its misery - The Pharma Letter
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN
Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com Nigeria
Bluebird bio stock plunges to 52-week low of $4.89 amid challenges - Investing.com Nigeria
Latham & Watkins Advises bluebird bio in Acquisition by Carlyle and SK Capital - Latham & Watkins LLP
Investment firms Carlyle and SK Capital to acquire gene therapy developer bluebird bio - BioProcess Insider
BofA moves to No Rating on Bluebird Bio after deal announcement - TipRanks
Dow Tumbles Over 700 Points; US Services PMI Falls In February - Benzinga
bluebird bio Sale to Carlyle and SK Capital Partners - Leerink Partners
Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones - TipRanks
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch -February 21, 2025 at 08:14 am EST - Marketscreener.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc.BLUE - PR Newswire
Struggling bluebird bio to go private for less than $30m - Pharmaceutical Technology
Cheap-cheap? Bluebird dodges bankruptcy with $30M buyout - BioWorld Online
Bluebird bio Agrees to be Acquired by Carlyle Group, SK Capital Partners; Shares Fall Sharply - Marketscreener.com
Bluebird bio to sell to investment funds after struggling to make money from gene therapies - Endpoints News
SK Capital Partners, LP and The Carlyle Group Inc. (NasdaqGS:CG) entered into an agreemet to acquire bluebird bio, Inc. - Marketscreener.com
Cash-strapped bluebird bio to be sold for less than $30M upfront - FirstWord Pharma
Once valued at $10B, bluebird bio sold to private equity firms for $29M - FiercePharma
Bluebird, at risk of default, agrees to take-private deal - BioPharma Dive
Once a darling of biotech, bluebird sells for less than $30M upfront - The Business Journals
Carlyle and SK Capital take bluebird bio private in $477m deal - Private Equity Insights
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch - KFGO
An awkward moment for Pfizer’s Bourla in Washington - STAT
Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M - BioSpace
Bluebird Bio downgraded to Neutral from Outperform at Baird - TipRanks
Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital - Marketscreener.com
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bluebird Bio Inc Stock (BLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Colvin Richard A | Chief Medical Officer |
Feb 03 '25 |
Sale |
7.39 |
64 |
473 |
8,194 |
| Vittiglio Joseph | Chief Business & Legal Officer |
Feb 03 '25 |
Sale |
7.39 |
238 |
1,759 |
4,501 |
| Obenshain Andrew | President and CEO |
Feb 03 '25 |
Sale |
7.39 |
86 |
636 |
18,485 |
1.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):